Breaking News Instant updates and real-time market news.

FMS

Fresenius Medical

$37.93

0.51 (1.36%)

08:25
11/08/19
11/08
08:25
11/08/19
08:25

Fresenius Medical participates in a conference call with JPMorgan

European MedTech Equity Analyst Adlington holds a conference call with CEO Powell on November 8 at 9 am hosted by JPMorgan.

  • 08

    Nov

FMS Fresenius Medical
$37.93

0.51 (1.36%)

02/21/19
RHCO
02/21/19
NO CHANGE
Target $48
RHCO
Buy
Fresenius Medical price target raised to $48 from $40 at SunTrust
SunTrust analyst David MacDonald raised his price target on Fresenius Medical to $48 and kept his Buy rating after its Q4 results yesterday, saying the quarter was "marked by solid organic trends, ongoing efficiency gains and strong cash flow." The analyst anticipates the company's 2019 to be a year of investment but sees the incremental spending driving more optimization and positioning Fresenius Medical for "attractive growth opportunities". MacDonald adds that he is positive on the company's pending acquisition of NxStage Medical (NXTM) given the market shift "towards the home".
06/20/19
LEHM
06/20/19
UPGRADE
LEHM
Overweight
Fresenius Medical upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Hassan Al-Wakeel upgraded Fresenius Medical Care to Overweight from Equal Weight and raised his price target for the shares to 81.50 euros from 71 euros. After speaking with CEO Rice Powell and a deep-dive into U.S. dialysis market fundamentals, the analyst believes market concerns around the medium-term sustainability of growth are likely overdone. The analyst has started to see some improvements in the business and believes expectations are now achievable. He now sees a "compelling" risk/reward over the medium term for shares of Fresenius Medical.
10/23/19
REDB
10/23/19
DOWNGRADE
REDB
Neutral
Fresenius Medical downgraded to Neutral from Buy at Redburn
Redburn analyst Ed Ridley-Day downgraded Fresenius Medical Care to Neutral from Buy.
10/23/19
REDB
10/23/19
DOWNGRADE
REDB
Neutral
Redburn downgrades Fresenius Medical to Neutral on growth concerns
Redburn analyst Ed Ridley-Day downgraded Fresenius Medical Care to Neutral from Buy and lowered his implied fair value estimate to 68 euros from 81 euros. Fresenius may not be able to achieve a return to high-single-digit earnings growth with pressure on margins likely to persist, Ridley-Day tells investors in a research note. He sees increasing risks around the company's U.S. dialysis business and limited potential recovery in Care Coordination.

TODAY'S FREE FLY STORIES

HBAYF

Hudson's Bay

$0.00

(0.00%)

15:46
12/13/19
12/13
15:46
12/13/19
15:46
Periodicals
Hudson's Bay take-private deal fails to secure investor support, Reuters says »

Hudson's Bay has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBAYF

Hudson's Bay

$0.00

(0.00%)

15:43
12/13/19
12/13
15:43
12/13/19
15:43
Periodicals
Breaking Periodicals news story on Hudson's Bay »

Hudson's Bay group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$7.48

-0.095 (-1.26%)

15:40
12/13/19
12/13
15:40
12/13/19
15:40
Periodicals
Deutsche Bank mulls deep cuts to bonuses this year, Bloomberg says »

Deutsche Bank is weighing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$163.03

-0.92 (-0.56%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:19
12/13/19
12/13
15:19
12/13/19
15:19
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

For the week, the Russell…

IWM

iShares Trust Russell 2000 Index Fund

$163.03

-0.92 (-0.56%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$60.31

-0.55 (-0.90%)

, XLB

S&P Select Materials SPDR

$60.50

-0.42 (-0.69%)

15:18
12/13/19
12/13
15:18
12/13/19
15:18
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX)…

XLE

Energy Select Sector SPDR

$60.31

-0.55 (-0.90%)

XLB

S&P Select Materials SPDR

$60.50

-0.42 (-0.69%)

XLK

Technology Select Sector SPDR

$89.50

0.61 (0.69%)

XLI

Industrial Select Sector SPDR

$81.67

-0.25 (-0.31%)

XLF

Financial Select Sector

$30.71

-0.11 (-0.36%)

XLU

Utilities SPDR

$63.39

0.53 (0.84%)

SPY

SPDR S&P 500 ETF Trust

$317.32

0.18 (0.06%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/13/19
12/13
15:17
12/13/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/13/19
12/13
15:16
12/13/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$49.35

-0.15 (-0.30%)

, NTNX

Nutanix

$32.95

0.34 (1.04%)

15:15
12/13/19
12/13
15:15
12/13/19
15:15
Periodicals
Dell looking to broaden infrastructure lead on Nutanix, CRN says »

Dell Technologies (DELL)…

DELL

Dell Technologies

$49.35

-0.15 (-0.30%)

NTNX

Nutanix

$32.95

0.34 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 16

    Dec

  • 09

    Jan

  • 27

    Feb

GOOS

Canada Goose

$40.14

-0.005 (-0.01%)

15:14
12/13/19
12/13
15:14
12/13/19
15:14
Periodicals
DA Davidson analyst sees Canada Goose prices falling, NY Post says »

DA Davidson analyst John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$357.87

-1.83 (-0.51%)

15:04
12/13/19
12/13
15:04
12/13/19
15:04
Periodicals
NHTSA to probe December 7 crash of Tesla Model 3, Reuters reports »

The agency will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 23

    Mar

LYV

Live Nation

$70.64

1.2 (1.73%)

15:02
12/13/19
12/13
15:02
12/13/19
15:02
Periodicals
DoJ preparing to take legal action against Live Nation over ticketing, WSJ says »

The Department of Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/13/19
12/13
15:00
12/13/19
15:00
General news
Treasury Market Summary »

Treasury Market Summary:…

LYV

Live Nation

$70.63

1.19 (1.71%)

14:57
12/13/19
12/13
14:57
12/13/19
14:57
Periodicals
DOJ preparing to take legal action against Live Nation over ticketing, WSJ says »

The Department of Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGRX

Eagle Pharmaceuticals

$59.90

0.73 (1.23%)

, LLY

Eli Lilly

$121.30

-0.39 (-0.32%)

14:55
12/13/19
12/13
14:55
12/13/19
14:55
Hot Stocks
Eagle Pharmaceuticals reports settlement agreement with Eli Lilly on Pemfexy »

Eagle Pharmaceuticals…

EGRX

Eagle Pharmaceuticals

$59.90

0.73 (1.23%)

LLY

Eli Lilly

$121.30

-0.39 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$64.01

0.05 (0.08%)

, GILD

Gilead

$65.67

-1.97 (-2.91%)

14:52
12/13/19
12/13
14:52
12/13/19
14:52
Periodicals
Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$64.01

0.05 (0.08%)

GILD

Gilead

$65.67

-1.97 (-2.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

BRFRF

Burford Capital

$0.00

(0.00%)

14:46
12/13/19
12/13
14:46
12/13/19
14:46
Hot Stocks
Muddy Waters' Block says still short Burford Capital »

Muddy Waters' Carson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANDE

Andersons

$24.03

-0.35 (-1.44%)

14:37
12/13/19
12/13
14:37
12/13/19
14:37
Hot Stocks
Andersons raises dividend to 17.5c from 17c per share »

The Andersons announces a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

, MDT

Medtronic

$113.56

1.17 (1.04%)

14:36
12/13/19
12/13
14:36
12/13/19
14:36
Recommendations
TNDM, Medtronic analyst commentary  »

Craig-Hallum reiterates…

TNDM

TNDM

MDT

Medtronic

$113.56

1.17 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

BMY

Bristol-Myers

$64.19

0.23 (0.36%)

, GILD

Gilead

$65.76

-1.88 (-2.78%)

14:30
12/13/19
12/13
14:30
12/13/19
14:30
Periodicals
Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says »

Bristol-Myers (BMY) was…

BMY

Bristol-Myers

$64.19

0.23 (0.36%)

GILD

Gilead

$65.76

-1.88 (-2.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/13/19
12/13
14:17
12/13/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/13/19
12/13
14:16
12/13/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOO

Vanguard S&P 500 ETF

$291.59

0.33 (0.11%)

, IVV

iShares Core S&P 500

$319.25

0.36 (0.11%)

14:08
12/13/19
12/13
14:08
12/13/19
14:08
Technical Analysis
On The Fly: ETF fund flow highlights »

For the second week,…

VOO

Vanguard S&P 500 ETF

$291.59

0.33 (0.11%)

IVV

iShares Core S&P 500

$319.25

0.36 (0.11%)

XLE

Energy Select Sector SPDR

$60.65

-0.21 (-0.35%)

XLF

Financial Select Sector

$30.74

-0.08 (-0.26%)

QQQ

Invesco QQQ Trust

$207.32

0.76 (0.37%)

SPY

SPDR S&P 500 ETF Trust

$317.43

0.29 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

14:01
12/13/19
12/13
14:01
12/13/19
14:01
Hot Stocks
Tandem Diabetes up 5% upon resumption following FDA approval news »

After resuming trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

14:00
12/13/19
12/13
14:00
12/13/19
14:00
Hot Stocks
Breaking Hot Stocks news story on TNDM »

Tandem Diabetes trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$218.24

-2.19 (-0.99%)

13:57
12/13/19
12/13
13:57
12/13/19
13:57
Hot Stocks
Vertex expands long-term CF medicines reimbursement agreement with Ireland »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.